Valuation: HLS Therapeutics Inc.

Market Cap 92.25M 79.91M 75.56M 68.41M 128M 8.85B 129M 902M 347M 4.49B 347M 339M 14.31B P/E 2026 *
-14.4x
P/E 2027 * -42.6x
Enterprise Value 92.25M 79.91M 75.56M 68.41M 128M 8.85B 129M 902M 347M 4.49B 347M 339M 14.31B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.42x
Free-Float
99.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week+9.26%
Current month+10.13%
1 month+5.90%
3 months-3.95%
6 months-6.14%
Current year-14.32%
1 week 3.7
Extreme 3.7
4.2
1 month 3.56
Extreme 3.56
4.2
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Buy

Compliance Officer

2,000 0.0064%
1/9/26 Buy

Chief Financial Officer

2,000 0.0064%
28/8/26 TaxCompany -2,000 0.0064% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%+9.26%-26.38%-17.73% 92.25M
-1.21%+1.06%+27.83%+113.86% 106B
-1.00%-3.27%+54.80%+165.09% 54.63B
+0.38%-1.86%-12.00%+264.14% 21.58B
-0.86%-2.05%-9.99%-9.49% 8.1B
-1.02%-3.71%-38.97%-33.71% 6.91B
-6.81%-5.15%-2.07%+14.40% 6.81B
-1.69%-4.67%-21.20%-29.65% 6.11B
-1.08%-0.18%-5.82%+19.22% 5.08B
-9.95%-22.20%+251.51%+382.23% 4.14B
Average -2.34%-1.53%+21.77%+86.84% 21.97B
Weighted average by Cap. -1.32%-3.26%+28.25%+127.91%

Financials

2026 *2027 *
Net sales 58.44M 50.62M 47.87M 43.33M 81.33M 5.61B 81.94M 571M 220M 2.84B 220M 215M 9.06B 65.03M 56.32M 53.26M 48.22M 90.5M 6.24B 91.18M 636M 245M 3.16B 244M 239M 10.09B
Net income -5.47M -4.74M -4.48M -4.06M -7.61M -525M -7.67M -53.46M -20.57M -266M -20.55M -20.09M -848M -2.16M -1.87M -1.77M -1.61M -3.01M -208M -3.04M -21.16M -8.14M -105M -8.13M -7.95M -336M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
16/09/26 CAD 4.130 -0.48% 240,279
14/09/26 CAD 4.150 +6.41% 54,491
11/09/26 CAD 3.900 +4.56% 144,351
10/09/26 CAD 3.730 -0.53% 30,665
09/09/26 CAD 3.750 -0.79% 17,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.982USD
Average target price
5.286USD
Spread / Average Target
+77.26%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!